VKTX · Viking Therapeutics, Inc.
$33.19
+0.25 (+0.76%)
At close · Aug 14
Market Cap
$3.87B
Shares
116.65M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Brian Lian | Chief Executive Officer | $21,269,833 |
| Marianne Mancini | Chief Operating Officer | $5,162,872 |
| Greg Zante | Chief Financial Officer | $5,135,872 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Brian Lian | Chief Executive Officer | $14,298,554 |
| Marianne Mancini | Chief | $4,703,394 |
| Greg Zante | Chief Financial Officer | $4,681,394 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Brian Lian | Chief Executive Officer | $12,628,061 |
| Marianne Mancini | Chief | $3,510,957 |
| Greg Zante | Chief Financial Officer | $3,495,957 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Brian Lian | Chief Executive Officer | $5,411,291 |
| Marianne Mancini | Chief | $2,052,044 |
| Greg Zante | Chief Financial Officer | $1,710,661 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Brian Lian | Chief Executive Officer | $4,059,119 |
| Marianne Mancini | Chief Operating Officer | $1,507,624 |
| Greg Zante | Chief Financial Officer | $1,345,330 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Brian Lian | Chief Executive Officer | $5,187,448 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Brian Lian | Chief Executive Officer | $3,512,119 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Brian Lian | Chief Executive Officer | $1,403,283 |
| Hiroko Masamune | Ph.D.^(^ ^)^ Former Chief Development Officer | $992,924 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Lawson Macartney, Ph.D. | Class III director | Appointed | 2024-05-23 |
| Brian Lian, Ph.D. | Class III director | Appointed | 2024-05-23 |
Key facts
CIK
1607678
CUSIP
92686J106
13F (30d)
402 filings
396 filers
Visit website
Investor relations